MedTrace Logo

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

NCT02140268 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2015-09-22

No results posted yet for this study

Summary

A Study to Evaluate the Effects of oral repeated doses of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

Midazolam

Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1

DRUG

AZD1722

Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14

DRUG

AZD1722 and Midazolam

On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.

Sponsors & Collaborators

  • Ardelyx

    lead INDUSTRY

Principal Investigators

  • Eleanor Lisbon, MD · Quintiles, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02140268 on ClinicalTrials.gov